105 related articles for article (PubMed ID: 22285179)
1. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients.
Wagner F; Henningsen B; Lederer C; Eichenmüller M; Gödeke J; Müller-Höcker J; von Schweinitz D; Kappler R
Eur J Cancer; 2012 Oct; 48(15):2442-50. PubMed ID: 22285179
[TBL] [Abstract][Full Text] [Related]
2. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
3. Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2.
Guo R; Wang T; Shen H; Ge HM; Sun J; Huang ZH; Shu YQ
Biomed Pharmacother; 2010 Apr; 64(4):249-53. PubMed ID: 19931998
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
6. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation.
Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O
Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445
[TBL] [Abstract][Full Text] [Related]
9. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
10. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.
Murphy JD; Spalding AC; Somnay YR; Markwart S; Ray ME; Hamstra DA
Clin Cancer Res; 2009 Jan; 15(2):589-96. PubMed ID: 19147764
[TBL] [Abstract][Full Text] [Related]
15. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro.
Zhang JF; Liu JJ; Lu MQ; Cai CJ; Yang Y; Li H; Xu C; Chen GH
Transpl Immunol; 2007 Apr; 17(3):162-8. PubMed ID: 17331842
[TBL] [Abstract][Full Text] [Related]
17. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
20. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.
Zeng Q; Yang Z; Gao YJ; Yuan H; Cui K; Shi Y; Wang H; Huang X; Wong ST; Wang Y; Kesari S; Ji RR; Xu X
Eur J Cancer; 2010 Apr; 46(6):1132-43. PubMed ID: 20156674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
